A biotechnology company focused on developing therapies to fully normalize CFTR function, targeting the NBD1, ICL4, and TMD1 regions of CFTR to achieve best-in-class efficacy for patients with cystic fibrosis.

Mark M.

Greg Hurlbut

Sionna Therapeutics

137 Ventures is a multi-stage venture capital firm, investing across sectors with flexible capital. The firm provides structured liquidity to founders and executives, transacting through direct secondaries and primary financings. The strategy offers founders a differentiated way to access liquidity versus traditional secondary.

137 Ventures

Renaissance Venture Capital focuses on providing capital and connecting venture capital firms with innovation companies and established businesses to support economic growth, self-described.

Renaissance Venture Capital

Visionary Ventures is a venture capital fund focused on investing in companies from series A to commercialization, aiming for investments that yield exceptional returns and address unmet or underserved markets. The company collaborates with Key Opinion Leaders and industry experts to inform their investment decisions.

Visionary Ventures

We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.

Atlas Venture

OrbiMed

T. Rowe Price

Cystic Fibrosis Foundation

The Rise Fund

TPG Rise Climate Fund

RA Capital Management

Managing a cystic fibrosis (#CF) diagnosis can be challenging. Jennifer, whose child is living with CF, has found ways to make the diagnosis less overwhelming. Read about her journey here: https://lnkd.in/dExcKR4g

At Sionna, we exercise our Core Values through our quarterly Culture Blasts. These events provide a way for us to come together regularly, learn about ourselves, practice our leadership skills and celebrate our achievements! 

During our most recent #CultureBlast in March, we had a great time celebrating our successful Series C financing and engaging in team bonding activities. Check out some pictures from the event!  

Just a few weeks after closing our Series C round, President & CEO Michael Cloonan reflected on the process of a private funding round and the key drivers of success including science, relationships and experience.  
 
Find the full post on the "From The Trenches" LifeSciVC blog organized by Bruce Booth of Atlas Venture: https://lnkd.in/es4mmfCz

We take calculated risks and purposefully explore creative ways to raise the bar for people living with cystic fibrosis (CF). In line with our core value of Intentional Innovation, Juliet Labadorf, Senior Director, Financial Planning & Analysis, shares a message about Sionna’s dynamic approach to CF therapeutic development.  

We are committed to the collective well-being of our entire team. That’s why we value flexibility, prioritize employee-driven ways of working, and offer policies designed to enhance work/life balance. 

Learn more about life at Sionna: https://lnkd.in/etdzEAVY 

Metric
Company Name	Sionna Therapeutics	137	Renaissance Venture Capital	Visionary Ventures
Symbol
MSH ID	COM:SIONNATX	COM:137VENTURES	COM:RENVCF	COM:VISIONARYVC
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	9	Financial Services & Finance	Financial Services & Finance	Financial Services & Finance
Industry	Healthcare & Health Services	Venture Capital	Venture Capital	Venture Capital
Country	US	US	US	US
Stage	Series C
Employee Count	31
Website	sionnatx.com	137ventures.com	renvcf.com	visionaryvc.com
LinkedIn	sionna-therapeutics
Founders

Metric
Market Cap	10.80M
Enterprise Value
Monthly Web Traffic	2.13K	943
Web Traffic Growth	0.56	-0.31
Valuation
Raised Capital	182M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:SIONNATX

Sionna Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue